Published On Apr 11, 2021
I sat down to interview the CEO of Senseonics company behind implantable CGM Eversense, Tim Goodnow and President & CEO of Eversense's global partner Ascensia company behind Contour glucose meters, Rob Schumm. The Eversense sensor is implanted in the upper arm for 90 days in the US and 180 days in Europe and they are working hard on the next generation sensor which will last for 365 days. Implanted sensor communicates to the on-body transmitter which communicates with an app. In this interview, we discuss how the system works from the insertion process. Tim also shared details about the so-called 'Gemini' sensor which eliminates the need for a transmitter altogether. I can't wait to hear your thoughts on this!
Video Credits:
• Video
• Eversense CGM System Overview
Learn more about Eversense: http://global.eversensediabetes.com
0:00 Intro
1:27 Overview
3:35 Sensor insertion
6:40 Transmitter
10:38 Global Partnership
13:44 Availability & Access
18:24 Closed Loop
21:45 365-day sensor plans
22:36 Project 'Gemini'
26:15 Insertion under the watch
28:03 Contour meters pipeline
Sign up to dQ&A and take part in surveys about diabetes- you can receive a gift card for each survey https://bit.ly/3s8YmgC ( link affiliated- I receive a small commission)
*******************************************
My email address: [email protected]
My Instagram: / nerdabetic
My Twitter: / nerdabetic
*******************************************